| Abstrakt: |
A recent report from a researcher at Link Campus University discusses the evaluation of genetic and genomic tests in personalized medicine. The systematic review identified 55 health technology assessment reports from countries like Australia, Canada, and the UK, focusing on pharmacogenomics and oncology. The study highlights the lack of a shared standard in evaluating genetic and genomic applications, emphasizing the need for a common methodology to comprehensively assess these technologies. The findings suggest a need to strengthen the evaluation of neglected dimensions, such as personal utility, ethical, legal, and social implications, to better define the value and risks of personalized medicine. [Extracted from the article] |
